Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher D Payne

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Journal of Cardiovascular Pharmacology|April 7, 2007
Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjectsJoseph A Jakubowski, Christopher D Payne, Govinda J Weerakkody, et al.
Journal of Cardiovascular Pharmacology|April 25, 2006
The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjectsJoseph A Jakubowski, Christopher D Payne, John T Brandt, et al.
British Journal of Clinical Pharmacology|November 23, 2012
A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivityJoseph A Jakubowski, Chunmei Zhou, David S Small, et al.
Journal of Cardiovascular Pharmacology|November 22, 2007
Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrelChristopher D Payne, Ying Grace Li, David S Small, et al.
Clinical and Translational Science|July 28, 2017
Prediction of Transporter-Mediated Drug-Drug Interactions for BaricitinibMaria M Posada, Ellen A Cannady, Christopher D Payne, et al.
Platelets|July 29, 2009
Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjectsYing G Li, Lan Ni, John T Brandt, et al.
Pharmacotherapy|November 26, 2008
Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjectsNagy A Farid, David S Small, Christopher D Payne, et al.
Clinical Pharmacology and Therapeutics|January 8, 2005
Effect of tadalafil on cytochrome P450 3A4-mediated clearance: studies in vitro and in vivoBarbara J Ring, Beverley E Patterson, Malcolm I Mitchell, et al.
European Journal of Clinical Pharmacology|November 6, 2009
The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjectsDavid S Small, Prajakti Kothare, Eunice Yuen, et al.
Clinical Therapeutics|March 9, 2010
Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trialDavid S Small, Christopher D Payne, Prajakti Kothare, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Journal of Cardiovascular Pharmacology|April 7, 2007
Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjectsJoseph A Jakubowski, Christopher D Payne, Govinda J Weerakkody, et al.
Journal of Cardiovascular Pharmacology|April 25, 2006
The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjectsJoseph A Jakubowski, Christopher D Payne, John T Brandt, et al.
British Journal of Clinical Pharmacology|November 23, 2012
A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivityJoseph A Jakubowski, Chunmei Zhou, David S Small, et al.
Journal of Cardiovascular Pharmacology|November 22, 2007
Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrelChristopher D Payne, Ying Grace Li, David S Small, et al.
Clinical and Translational Science|July 28, 2017
Prediction of Transporter-Mediated Drug-Drug Interactions for BaricitinibMaria M Posada, Ellen A Cannady, Christopher D Payne, et al.
Platelets|July 29, 2009
Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjectsYing G Li, Lan Ni, John T Brandt, et al.
Pharmacotherapy|November 26, 2008
Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjectsNagy A Farid, David S Small, Christopher D Payne, et al.
Clinical Pharmacology and Therapeutics|January 8, 2005
Effect of tadalafil on cytochrome P450 3A4-mediated clearance: studies in vitro and in vivoBarbara J Ring, Beverley E Patterson, Malcolm I Mitchell, et al.
European Journal of Clinical Pharmacology|November 6, 2009
The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjectsDavid S Small, Prajakti Kothare, Eunice Yuen, et al.
Clinical Therapeutics|March 9, 2010
Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trialDavid S Small, Christopher D Payne, Prajakti Kothare, et al.
Pageof 4